Dr James Hrastelj
Prosiectau fel Cyd-Ymchwiliwr
- Gene expression regulation in CD4+ T cell dysfunction in multiple sclerosis (01.10.2017 - 30.09.2018)
- TG1101-RMS302 Phase III: UbLiTuximab in Multiple Sclerosis treatment effects (ULTIMATE II STUDY) (11.01.2019 - 31.01.2021)
Thomson Reuters Deutschland GmbH
Zur Giesserei 2
D-76227 Karlsruhe | Germany